# A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma

> **NCT03519997** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **David Hsieh** · enrollment: 35 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Bavituximab

## Key facts

- **NCT ID:** NCT03519997
- **Lead sponsor:** David Hsieh
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-04-26
- **Primary completion:** 2023-04-21
- **Final completion:** 2026-04-01
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2026-02-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03519997

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03519997, "A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03519997. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*